Century Therapeutics, Inc. (IPSC) Key Metrics
IPSC valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $248.1M
- Enterprise value
- $237.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.7 10-yr median 57.0
- Price / book
- 1.4 10-yr median 1.0
- EV / EBITDA
- 131.5
- Dividend yield
- —
- Beta
- 1.67
IPSC key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIPSC valuation Price multiples at each fiscal year-end price.
IPSC returns How much profit the business earns on the capital it uses.
IPSC per-share figures Results divided by the shares outstanding at year-end.
IPSC financial health Debt, liquidity and how easily interest is covered.
IPSC efficiency & capital use Working capital cycle and where the cash goes.
IPSC valuation history
IPSC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IPSC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IPSC price vs earnings per share
IPSC key metrics
2015–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $86.1M | $79.4M | $196.9M | $296.3M | $872.4M | — | — | — | — |
| Enterprise value | $12.6M | −$56.0M | $72.4M | $30.2M | $674.6M | — | — | — | — |
| Price / sales | 0.8 | 12.1 | 88.1 | 57.0 | 824.6 | — | — | — | — |
| Price / book | 0.5 | 0.5 | 1.1 | 1.0 | 2.2 | — | — | — | — |
| Price / operating cash flow | — | — | — | 21.1 | — | — | — | — | — |
| EV / sales | 0.1 | -8.5 | 32.4 | 5.8 | 637.6 | — | — | — | — |
| EV / EBITDA | 3.6 | — | — | — | — | — | — | — | — |
| Earnings yield | −11.1% | −159.3% | −69.4% | −44.2% | −11.0% | — | — | — | — |
| Free cash flow yield | −121.6% | −138.8% | −51.8% | −5.6% | −15.4% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $0.99 | $1.01 | $3.32 | $5.13 | $15.86 | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $1.26 | $0.08 | $0.04 | $0.09 | $0.02 | $0.00 | $0.00 | — | — |
| Earnings per share | −$0.11 | −$1.61 | −$2.30 | −$2.27 | −$1.74 | −$0.98 | −$4.46 | — | — |
| Operating cash flow per share | −$1.20 | −$1.40 | −$1.49 | $0.24 | −$1.62 | −$0.75 | −$0.29 | — | — |
| Free cash flow per share | −$1.21 | −$1.40 | −$1.72 | −$0.29 | −$2.44 | −$0.93 | −$0.34 | — | — |
| Cash per share | $1.35 | $2.41 | $2.91 | $5.46 | $4.05 | $1.38 | $1.49 | — | — |
| Book value per share | $1.84 | $2.05 | $3.11 | $5.24 | $7.20 | −$1.94 | −$1.68 | — | — |
| Tangible book value per share | $1.44 | $1.62 | $3.11 | $5.24 | $7.20 | −$2.11 | −$1.68 | — | — |
| Capex per share | $0.01 | $0.00 | $0.23 | $0.53 | $0.82 | $0.18 | $0.04 | — | — |
| Debt per share | $0.50 | $0.68 | $0.81 | $0.86 | $0.46 | $0.39 | — | — | — |
| Shares outstanding | 86.6M | 78.6M | 59.3M | 57.8M | 55.0M | 54.8M | 54.8M | — | — |
| Change in shares outstanding | +10.1% | +32.6% | +2.7% | +5.0% | +0.3% | 0.0% | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −6.0% | −73.1% | −56.1% | −37.5% | −66.1% | — | — | — | — |
| Return on invested capital (ROIC) | −21.4% | −253.5% | −239.1% | −89.9% | −395.9% | — | — | — | — |
| Return on assets (ROA) | −3.3% | −35.5% | −32.3% | −28.3% | −35.2% | −54.2% | −57.7% | — | — |
| Return on tangible assets | −5.1% | −39.7% | −37.9% | −26.9% | −21.9% | −55.0% | −269.3% | — | — |
| Free cash flow margin | −95.9% | — | — | −318.4% | — | — | — | — | 7.9% |
| Financial health | |||||||||
| Total debt | $43.6M | $53.8M | $48.2M | $49.4M | $25.1M | $21.6M | — | $275.4M | $156.3M |
| Cash & short-term investments | $117.1M | $189.3M | $172.7M | $315.5M | $222.9M | $75.8M | $81.5M | $21.5M | $208,000 |
| Net debt | −$73.5M | −$135.5M | −$124.6M | −$266.1M | −$197.8M | −$54.2M | −$81.5M | $253.9M | $156.1M |
| Debt / equity | 0.27 | 0.33 | 0.26 | 0.16 | 0.06 | — | — | 1.51 | 0.43 |
| Debt / assets | 0.19 | 0.15 | 0.13 | 0.10 | 0.06 | 0.20 | — | 0.36 | 0.19 |
| Net debt / EBITDA | −21.30 | — | — | — | — | — | — | — | — |
| Current ratio | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 | — | — |
| Quick ratio | 5.97 | 1.50 | 9.92 | 10.72 | 14.59 | 6.35 | 27.32 | — | — |
| Interest coverage | — | — | -271.4 | -121.1 | -74.4 | -129.1 | — | — | — |
| Working capital | $100.5M | $64.3M | $159.1M | $289.9M | $212.5M | $66.7M | $81.1M | — | — |
| Invested capital | $85.4M | $25.9M | $60.2M | $36.7M | $198.5M | −$160.6M | −$173.4M | $436.4M | $515.8M |
| Tangible asset value | $124.7M | $127.2M | $184.8M | $302.7M | $396.2M | −$115.8M | −$91.9M | $166.6M | $322.7M |
| Net current asset value | $56.0M | $2.2M | $1.1M | $135.9M | $187.0M | −$134.4M | −$98.6M | — | — |
| Graham net-net per share | $0.61 | −$0.02 | −$0.05 | $2.29 | $3.31 | −$2.48 | −$1.82 | — | — |
| Capital allocation | |||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | — | — | — | — |
| Capex / revenue | 0.8% | 2.3% | 614.6% | 588.7% | 4,250.5% | — | — | 2.4% | 3.1% |
| Capex / operating cash flow | — | — | — | 217.8% | — | — | — | — | 28.2% |
| Capex / depreciation | 0.06 | 0.01 | 1.05 | 3.63 | 12.00 | 7.01 | 9.88 | — | — |
| Stock-based compensation / revenue | 6.3% | 192.6% | 654.2% | 205.2% | 440.6% | — | — | — | — |
| R&D / revenue | 87.6% | 1,627.6% | 4,148.1% | 1,869.1% | 7,150.1% | — | — | 1.9% | 1.2% |
| SG&A / revenue | 22.0% | 503.2% | 2,136.5% | 612.8% | 1,818.1% | — | — | 17.3% | 11.4% |
| Efficiency | |||||||||
| Days sales outstanding | 3.7 | 60.5 | 118.0 | 36.2 | 199.7 | — | — | — | — |
| Days of inventory on hand | — | — | — | — | 64.9 | 438.7 | 143,063.9 | 186.7 | 117.4 |
| Days payables outstanding | 109.3 | 79.8 | 114.7 | 236.5 | 624.5 | 1,002.0 | 42,085.7 | 38.6 | 17.7 |
| Cash conversion cycle (days) | -105.7 | -19.3 | 3.3 | -200.3 | -359.8 | — | — | — | — |
| Receivables turnover | 99.83 | 6.03 | 3.09 | 10.10 | 1.83 | 0.00 | 0.00 | — | — |
| Payables turnover | 3.34 | 4.57 | 3.18 | 1.54 | 0.58 | 0.36 | 0.01 | 9.46 | 20.65 |
| Inventory turnover | — | — | — | — | — | 0.83 | 0.00 | 1.95 | 3.11 |
| Asset turnover | 0.38 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.59 | 1.13 |
| Average receivables | $1.1M | $1.1M | $722,500 | $515,000 | $579,000 | $515,500 | $123,000 | — | — |
| Average payables | $3.9M | $2.9M | $4.1M | $6.5M | $7.8M | $4.8M | $28.7M | $49.5M | $43.0M |
| Average inventory | — | — | — | — | $815,000 | $2.1M | $97.6M | $239.3M | $285.8M |
| Intangibles / total assets | 15.3% | 9.7% | 0.0% | 0.0% | 0.0% | 8.8% | 0.0% | 2.1% | 4.4% |
Computed from IPSC's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IPSC valuation and financial ratios
Century Therapeutics earned a return on equity of −6.0% and a return on invested capital of −21.4% in fiscal 2025. It ended the year with $43.6 million of debt and $117.1 million in cash and short-term investments, a net cash position of $73.5 million.
See the IPSC income statement, the IPSC chart for price history, or the IPSC stock overview for the latest quote and news.
IPSC key metrics FAQ
What is Century Therapeutics's EV/EBITDA?
Century Therapeutics's enterprise value was 3.6 times EBITDA at the end of fiscal 2025 (enterprise value $12.6 million, EBITDA $3.5 million); the current EV/EBITDA is 131.5.
What is Century Therapeutics's return on equity?
Century Therapeutics's return on equity (ROE) was −6.0% in fiscal 2025: net income of -$9.6 million on average shareholders' equity of $160.1 million.
What is Century Therapeutics's ROIC?
Century Therapeutics's return on invested capital was −21.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Century Therapeutics have?
Century Therapeutics had total debt of $43.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.27 and more cash than debt.
What is Century Therapeutics's free cash flow yield?
Century Therapeutics generated -$104.7 million of free cash flow in fiscal 2025, a free cash flow yield of −121.6% on its market value at year-end ($86.1 million).
What is Century Therapeutics's current ratio?
Century Therapeutics's current ratio was 5.97 at the end of fiscal 2025: current assets were 5.97 times current liabilities.